Search PubMed⌕ Search

Biomedical subjects

I Uchida

Publications and source records attributed to I Uchida.

At least 127 records · Page 7Linked to original sources
PubMed1985

Studies on WB-3559 A, B, C and D, new potent fibrinolytic agents. I. Discovery, identification, isolation and characterization.

WB-3559 A, B, C and D were produced by a bacterium which was classified as a member of the genus Flavobacterium. These compounds were purified by solvent extraction followed by chromatography on silica gel and then isolated by HPLC. The chemical structures were determined on the basis of chemical and spectroscopic evidence as in the succeeding papers. WB-3559 A, B, C and D stimulated rabbit plasma euglobulin clot lysis time. A chemically synthesized compound (WB-3559 D-syn) stimulated mouse plasma euglobulin clot lysis time when injected intravenously.

Animals↗
PubMed1985

New antitumor antibiotics, FR-900405 and FR-900406. II. Production, isolation, characterization and antitumor activity.

The new antitumor antibiotics, FR-900405 and FR-900406, were isolated from the culture broth of Actinomadura pulveracea sp. nov. No. 6049. These compounds which contain sulfur in the molecule, represent a novel class of antitumor agents. FR-900405 and FR-900406 are highly active in mice against experimental tumors and exhibit antimicrobial activity against Gram-positive and Gram-negative bacteria and fungi.

Actinomycetales↗
PubMed1984

Chryscandin, a novel peptidyl nucleoside antibiotic. II. Structure determination and synthesis.

The structure of chryscandin, a novel antifungal antibiotic, produced by Chrysosporium pannorum No. 4629 was deduced to be 1 from spectroscopic and chemical evidences. In order to confirm the structure and to determine the absolute configuration, the total synthesis of chryscandin was performed. D-Xylose was transformed into 10 in ten steps. After beta-glycosidation of silylated benzoyl adenine with 10, the resulting 11 was converted into 4, which was identical with the product obtained from chryscandin by alkaline hydrolysis. From the key intermediate 13, chryscandin was synthesized via peptide formation followed by removal of the protecting groups. Chryscandin (1) is the first naturally occurring nucleoside antibiotic possessing a 3-aminoribofuranuronic acid in the molecule.

Antifungal Agents↗
PubMed1983

[Intra-arterial infusion through 2 routes in liver (primary and metastatic cancer].

Patients with unresectable liver cancer (primary and metastatic) were treated with a newly-devised arterial infusion chemotherapy using Cis-DDP and its antidote Sodium thiosulfate (STS). The patients consisted of 4 with primary hepatoma and 1 with metastatic liver cancer originated from intestinal cancer. For the purpose of reducing unfavourable side effects without changing anticancer effect, Cis-DDP was infused into hepatic artery through the catheter while STS being administered systemically. According to Koyama and Saito's criteria, 2 of 5 patients showed partial response (PR) and the others showed no change (NC). The median survival time after onset of therapy was 6.6 months ranging from 2 to 11 months in all the patients. The myelosuppression and renal toxicity, which were considered to be the most serious side effects of Cis-DDP, were not found and liver function was not affected in all the patients. However, all the patients complained of nausea and vomiting. Thus, our experience has indicated that this newly devised infusion chemotherapy is a promising method for treating unresectable liver cancer, although further efforts are necessary for reducing the gastrointestinal toxicity.

Adult↗
PubMed1982

Cross-protection against fecal excretion of Yersinia enterocolitica and Yersinia pseudotuberculosis in mice by oral vaccination of viable cells.

Mice given orally either the O3, O9, or O5B serovar of Yersinia enterocolitica showed protection upon subsequent oral challenge with another of these strains. Excretion of serovar O3 in the feces was inhibited in mice surviving oral challenge with Yersinia pseudotuberculosis IVA. Cross-reaction of O antigen among these four strains was 32 or more times lower than the homologous titers.

Animals↗